Journal Article Summary
The article discusses advancements in the synthesis of O-desmethylvenlafaxine succinate monohydrate (DVS), a key compound used in treating major depressive disorder and anxiety. This topic is significant because DVS is the active metabolite of venlafaxine, a widely prescribed antidepressant. Improving the synthesis process and quality standards of DVS can enhance its safety and efficacy, making it a preferred choice for healthcare providers in managing mental health conditions.
The researchers optimized a five-step synthesis process for DVS, starting from p-hydroxybenzene acetonitrile. They achieved high yields and purity levels for each intermediate compound involved in the synthesis, with the final product reaching a purity of 99.92% and a yield of 90.27%. The methods used were designed to minimize environmental impact and reduce the presence of harmful impurities, which is crucial for ensuring the safety of the final pharmaceutical product.
Despite these advancements, the study has limitations, including the need for further validation in larger-scale industrial settings. Patients should be aware that while the synthesis process has been improved, the safety and effectiveness of the drug still depend on proper usage and monitoring by healthcare professionals. It is advisable for patients and caregivers to discuss any concerns regarding medications, including potential side effects and interactions, with their healthcare provider to ensure safe and effective treatment.
Medication Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Yang Shiwei, Chen Shiyun, Wang Cheng, Zhang Shibo, Li Shuaifei, Yuan Xinsong, Peng Fuyun, He Yong. Advances in Research at Synthesis Process Optimization and Quality Standard Improvement of O-desmethylvenlafaxine Succinate. Frontiers in Chemistry 2022. DOI: 10.3389/fchem.2022.860292. PMID: 36059880. PMCID: PMC9428404.
Featured Pill Pals Product
Desvenlafaxine Succinate Extended Release 50 mg Tablets --- 30 Count --- Generic for Pristiq --- Slate Run Pharma
Desvenlafaxine Succinate Extended Release 50 mg Tablets — 30 Count — Generic for Pristiq — Slate Run Pharma is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. Prescription required.
Request a prescription transfer and our pharmacy team will help coordinate the next step.
